Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspecs GroupLSE:SPEC 45 Days Sales Outstanding is 47.72 as of Jun. 2026, which is 11% below its 10-year median of 53.73. GuruFocus rates LSE:SPEC with a GF Score™ of 45/100 and a GF Value™ of £0.56 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 809 Medical Devices & Instruments companies, Inspecs Group ranks better than 69.47% on this metric.
Inspecs Group's average Accounts Receivable for the
six
months ended in Jun. 2026 was £25.9 Mil. Inspecs Group's Revenue for the
six
months ended in Jun. 2026 was £99.1 Mil.
Hence, Inspecs Group's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 47.72.
The historical rank and industry rank for Inspecs Group's Days Sales Outstanding or its related term are showing as below:
LSE:SPEC'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.18 Med: 53.73 Max: 136.07
Current: 48.57
During the past 10 years, Inspecs Group's highest Days Sales Outstanding was 136.07. The lowest was 40.18. And the median was 53.73.
LSE:SPEC's Days Sales Outstanding is ranked better than 69.47% of 809
companies
in the Medical Devices & Instruments industry
Industry Median: 64.94
vs LSE:SPEC: 48.57
Inspecs Group's Days Sales Outstanding
declined
from Jun. 2025 (48.81) to Jun. 2026 (47.72).
Inspecs Group (LSE:SPEC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Inspecs Group Days Sales Outstanding Related Terms
Inspecs Group Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Inspecs Group's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:SPEC vs ISRG, BDX, RMD: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Inspecs Group's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspecs Group (LSE:SPEC) has a Days Sales Outstanding of 47.72 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Inspecs Group and its competitors. This is 11% below median its historical median of 53.73. Over the past decade, Inspecs Group's Days Sales Outstanding has ranged from 40.18 to 136.07. According to the industry distribution chart, Inspecs Group ranks #247 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is Inspecs Group's Days Sales Outstanding too high?
Inspecs Group's current Days Sales Outstanding of 47.72 is 11% below median its 10-year median of 53.73. Over the past 10 years, this metric has ranged from a low of 40.18 to a high of 136.07. The Medical Devices & Instruments industry median Days Sales Outstanding is 64.94. Inspecs Group's value of 47.72 is 26.5% below this industry median. Based on the distribution chart, Inspecs Group ranks #247 out of 809 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Inspecs Group has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #247 out of 809 companies for Days Sales Outstanding. This puts Inspecs Group in the upper half of its industry. The industry median Days Sales Outstanding is 64.94. Inspecs Group's value of 47.72 is 26.5% below this benchmark. Historically, Inspecs Group's own Days Sales Outstanding has ranged from 40.18 to 136.07 over the past decade. While the company's 10-year median is 53.73 vs. the industry median of 64.94, Inspecs Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 64.94, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspecs Group's current Days Sales Outstanding of 47.72 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Inspecs Group and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 64.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current Days Sales Outstanding is 47.72, which is 11% below median its own 10-year median of 53.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Based on GuruFocus' analysis, Inspecs Group (LSE:SPEC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.56, compared to a current price of £0.96 — trading 71.4% above its estimated fair value. The current Days Sales Outstanding is 47.72, which is 11% below median its 10-year median of 53.73 and 26.5% below the Medical Devices & Instruments industry median of 64.94. Inspecs Group's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Inspecs Group (LSE:SPEC), the current Days Sales Outstanding is 47.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (LSE:SPEC) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of £0.96 is trading 71.4% above its estimated GF Value™ of £0.56.
GuruFocus considers Inspecs Group to be Significantly Overvalued.
Key valuation signals for LSE:SPEC:
Days Sales Outstanding: 47.72 (11% below median its 10-year median of 53.73)
GF Value™: £0.56 vs. price of £0.96 (71.4% above fair value)
Industry Position: 26.5% below the Medical Devices & Instruments median (#247 of 809)
No single metric tells the full story. See the LSE:SPEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
45GF Score
Get the complete analysis for LSE:SPEC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SPEC has been successfully added to your 
